A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)

Trial Profile

A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs PF 4958242 (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Oct 2016 Status changed from not yet recruiting to discontinued.
    • 09 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top